ロード中...
Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel
BACKGROUND: In recent years treatment options for advanced pancreatic cancer have markedly improved, and a combination regimen of gemcitabine and nab-paclitaxel is now considered standard of care in Sweden and elsewhere. Nevertheless, a majority of patients do not respond to treatment. In order to g...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7530950/ https://ncbi.nlm.nih.gov/pubmed/33008332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07426-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|